SA
LGND icon

Scarborough Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Scarborough Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33
Closed -$6.59K – 432
2026
Q1 		$6.59K Hold
33
– – ﹤0.01% 490
2025
Q4 		$6.24K Hold
33
– – ﹤0.01% 299
2025
Q3 		$5.85K Hold
33
– – ﹤0.01% 295
2025
Q2 		$3.75K Buy
+33
New +$3.53K ﹤0.01% 312
2024
Q3 		– Sell
-33
Closed -$2.78K – 296
2024
Q2 		$2.78K Hold
33
– – ﹤0.01% 287
2024
Q1 		$2.41K Hold
33
– – ﹤0.01% 295
2023
Q4 		$2.36K Buy
+33
New +$1.95K ﹤0.01% 557

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Scarborough Advisors's LGND Position: Q2 2026 in Review

Scarborough Advisors sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 33 shares — an estimated $6.59K sold.

Scarborough Advisors first reported a position in LGND in Q4 2023 and held it in 7 quarters. The position peaked at $6.59K in Q1 2026. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Scarborough Advisors reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 33 Ligand Pharmaceuticals shares in Q2 2026, an estimated $6.59K.
  • Scarborough Advisors first reported a position in Ligand Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Scarborough Advisors's Ligand Pharmaceuticals position peaked at $6.59K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.